Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).
This retrospective study performed by the Eastern Cooperative Oncology Group and the Southwest Oncology Group enrolled 140 acute promyelocytic leukemia (APL) patients with t(15;17) to determine the influence of additional karyotypic abnormalities on treatment outcome. Karyotypes were centrally reviewed by both study groups. The complete response rate after induction for patients with t(15;17) treated with chemotherapy, or all-trans retinoic acid (ATRA) as induction therapy was not affected by additional cytogenetic aberrations. Disease-free (DFS) and overall survival (OS) were unaffected by additional cytogenetic abnormalities if treatment was chemotherapy without ATRA. Patients with t(15;17) only, treated with ATRA with or without chemotherapy, had an improved DFS (P = 0.06) and a better OS (P = 0.01) compared with ATRA-treated patients with additional cytogenetic abnormalities. Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities.
Continuum Cancer Centers of New York at St. Lukes, Roosevelt and Beth Israel Medical Centers, Roosevelt Hospital Center, Ste 11C-02, 1000 10th Ave., New York, NY 10019, USA. pwiernik@chpnet.org
Peter H
PH
Wiernik
Zhuoxin
Z
Sun
Holly
H
Gundacker
Gordon
G
Dewald
Marilyn L
ML
Slovak
Elisabeth
E
Paietta
Haesook T
HT
Kim
Frederick R
FR
Appelbaum
Peter A
PA
Cassileth
Martin S
MS
Tallman
D059786:Abnormal Karyotype; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D014212:Tretinoin / Q000627:therapeutic use; D055815:Young Adult
D000970:Antineoplastic Agents; D014212:Tretinoin